<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9074">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05705804</url>
  </required_header>
  <id_info>
    <org_study_id>4-2022-1325</org_study_id>
    <nct_id>NCT05705804</nct_id>
  </id_info>
  <brief_title>Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial</brief_title>
  <official_title>Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to investigate the effect of pitavastatin or pitavastatin and&#xD;
      ezetimibe combination therapy on glucose metabolism compared to atorvastatin in patients with&#xD;
      atherosclerotic cardiovascular disease with metabolic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2023</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change form baseline homeostatic model assessment for insulin resistance (HOMA-IR) at 24 weeks</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>Changes of homeostatic model assessment for insulin resistance (HOMA-IR) form baseline to 24 weeks will be compared among the three groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of fasting glucose ≥100 mg/dL</measure>
    <time_frame>At 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of HbA1C ≥6.5%</measure>
    <time_frame>At 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of new-onset diabetes mellitus</measure>
    <time_frame>At 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of HOMA-β at 24 weeks</measure>
    <time_frame>At 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of fasting glucose at 24 weeks</measure>
    <time_frame>At 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of insulin at 24 weeks</measure>
    <time_frame>At 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of HbA1c at 24 weeks</measure>
    <time_frame>At 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of triglyceride at 24 weeks</measure>
    <time_frame>At 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-cholesterol change at 24 weeks</measure>
    <time_frame>At 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-cholesterol change at 24 weeks</measure>
    <time_frame>At 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pitavastatin 4mg group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group PE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pitavastatin 4 mg Ezetimibe 10 mg combined administration group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 40 mg administration group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>Pitavastatin 4 mg will be given.</description>
    <arm_group_label>Group P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin plus Ezetemibe</intervention_name>
    <description>Pitvastatin 4 mg plus ezetemibe 10 mg will be given.</description>
    <arm_group_label>Group PE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 40 mg will be given.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with dyslipidemia&#xD;
&#xD;
          2. Patient with diagnosis of clinical atherosclerotic cardiovascular disease (acute&#xD;
             coronary syndrome, history of myocardial infarction, stable or unstable angina,&#xD;
             history of coronary artery reperfusion, stroke or transient stroke, history of&#xD;
             peripheral arterial disease or peripheral arterial reperfusion)&#xD;
&#xD;
          3. Patients with metabolic syndrome but without diabetes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of clinical atherosclerotic cardiovascular disease within 1 year&#xD;
&#xD;
          2. Acute liver disease or persistent unexplained serum AST or ALT twice the upper limit&#xD;
             of normal&#xD;
&#xD;
          3. Allergy or hypersensitivity to statins or ezetimibe&#xD;
&#xD;
          4. Solid organ transplant recipients&#xD;
&#xD;
          5. History of side effects requiring discontinuation of statin administration&#xD;
&#xD;
          6. Pregnant women, potentially pregnant or lactating women&#xD;
&#xD;
          7. Life expectancy less than 3 years&#xD;
&#xD;
          8. If it is judged that follow-up for more than 1 year is not possible&#xD;
&#xD;
          9. If the patient is unable to understand or read the consent form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byeong-Keuk Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Cardiovascular Hospital, YONSEI UNIVERSITY COLLEGE OF MEDICINE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Byeong-Keuk Kim</last_name>
    <phone>82-2-2228-8465</phone>
    <email>KIMBK@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Byeong-Keuk Kim</last_name>
      <phone>82-2-2228-8465</phone>
      <email>KIMBK@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 18, 2023</study_first_submitted>
  <study_first_submitted_qc>January 29, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2023</study_first_posted>
  <last_update_submitted>January 29, 2023</last_update_submitted>
  <last_update_submitted_qc>January 29, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

